| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $3,324,591 ) |
| | 2024 | 2024 | PARK THERAPEUTICS INC. | 2031 US HIGHWAY 130 | MONMOUTH JUNCTION | NJ | 08852-3014 | MIDDLESEX | USA | UG3DA059285 | Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | 003 | 2 | NIH | 8/28/2024 | $0 |
| | 2024 | 2024 | PARK THERAPEUTICS INC. | 2031 US HIGHWAY 130 | MONMOUTH JUNCTION | NJ | 08852-3014 | MIDDLESEX | USA | UG3DA059285 | Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | 002 | 2 | NIH | 8/7/2024 | $3,324,591 |
| | 2024 | 2023 | PARK THERAPEUTICS INC. | 2031 US HIGHWAY 130 | MONMOUTH JUNCTION | NJ | 08852-3014 | MIDDLESEX | USA | UG3DA059285 | Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | 001 | 1 | NIH | 11/14/2023 | $0 |
| | 2024 | 2023 | PARK THERAPEUTICS INC. | 2031 US HIGHWAY 130 | MONMOUTH JUNCTION | NJ | 08852-3014 | MIDDLESEX | USA | UG3DA059285 | Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | 000 | 1 | NIH | 10/11/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,329,591 ) |
| | 2023 | 2023 | PARK THERAPEUTICS INC. | 2031 US HIGHWAY 130 | MONMOUTH JUNCTION | NJ | 08852-3014 | MIDDLESEX | USA | UG3DA059285 | Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | 000 | 1 | NIH | 8/2/2023 | $3,329,591 |
| | 2023 | 2023 | PARK THERAPEUTICS INC. | 2031 US HIGHWAY 130 | MONMOUTH JUNCTION | NJ | 08852-3014 | MIDDLESEX | USA | UG3DA059285 | Development of cebranopadol, a potent dual MOP/NOP agonist, for the treatment of Opioid Use Disorder (OUD) | 001 | 1 | NIH | 8/30/2023 | $0 |
|
|
